BofA Consumer Banking Data on Health, DH Target Cut
Bank of America Institute’s latest Consumer Checkpoint reports show U.S. consumers in solid financial shape despite moderating spending growth, with February 2026 card spending up 3.2% year-over-year-the strongest in over three years.[5] This BofA consumer banking health data contrasts with BofA Securities’ recent price target cut on Definitive Healthcare (DH) to $3.50 from $4.00, driven by the company’s weak 2026 guidance.[1] No high-credibility sources link this directly to Colgate-Palmolive (CL) or Chubb (CB) target cuts; searches confirm no recent BofA actions on those stocks, shifting focus to verified DH developments and broader consumer trends.
Overview
- Spending growth accelerated: February 2026 YoY card spending per household hit 3.2%, highest in over three years, with 0.9% month-over-month seasonally adjusted rise per BofA data.[5]
- DH revenue beat but guidance miss: Q4 2025 revenue at $61.5 million topped estimates, yet 2026 guidance 5% below consensus on revenue, 15% below on adjusted EBITDA.[1]
- Customer base contracted: DH total customers fell to 2,330 from 2,400 in Q3 2025; enterprise customers dropped to 511 from 520.[1]
- Income spending gaps persist: Higher-income households saw 2.6% YoY spending growth in November 2025 vs. 0.6% for lower-income, with wage growth at 4% vs. 1.4%.[4]
- Credit health mixed: More consumers pay off BofA credit cards monthly, but minimum payments share rises, signaling stress for some households.[2][5]
- DH valuation adjustment: BofA cut DH target to 8.0x CY2026E EBITDA from 10.5x prior, citing peer multiple compression and outlook.[1]
Subscribe to our Social Media for Exclusive Crypto News and Insights 24/7!
BofA Consumer Banking Health Data Trends
Bank of America Institute tracks aggregated credit and debit card data to gauge real-time consumer behavior. February’s BofA consumer banking health data marked a rebound: total spending per household grew 3.2% YoY, up from prior months, with strong 0.9% MoM seasonally adjusted gains.[5] This followed November 2025’s 1.3% YoY slowdown, where higher-income cohorts drove momentum at 2.6% while lower-income lagged at 0.6%.[4]
Lower-income households face wage deceleration-1.3% YoY in July 2025 versus 3.2% for higher-income-yet overall deposits remain elevated with borrowing capacity intact.[3] April 2025 data showed 1% YoY spending growth, flat month-over-month, as consumers pulled back on big-ticket items like airlines and lodging.[2] Tax refunds in early 2026 boosted lower-income discretionary spending more than higher-income, temporarily narrowing gaps.[5]
A key metric: the share of households making only minimum credit card payments has increased, per BofA card data, even as more pay balances fully.[2][5] This points to margin pressures without broad distress.
Definitive Healthcare Target Cut Details
BofA Securities lowered its DH price target amid the stock’s slump to $0.95, just 3% above its 52-week low of $0.92.[1] The firm kept a Buy rating but adjusted to 8.0x CY2026E EBITDA, down from 10.5x, reflecting lower guidance and peer multiples.[1] DH’s Q4 2025 revenue hit $61.5 million, beating estimates and guidance, but EPS missed at -$0.09 versus $0.06 expected.[1]
Guidance disappointed: 2026 revenue 5% below consensus, adjusted EBITDA 15% below.[1] Customers shrank sequentially, with life sciences segment weak despite provider and diversified growth; renewals improved for three quarters, gross dollar retention up 2% YoY.[1] Board changes included Jeff Haywood’s resignation without disagreements, ending a nominating agreement and trimming directors to eight.[1]
Other analysts reacted: BTIG held Neutral, Stephens cut target to $2.00 from $3.00 on revenue declines.[1]
Consumer Data vs. DH Performance Comparison
BofA consumer banking health data paints a resilient picture, yet DH-a healthcare analytics firm reliant on life sciences and providers-struggles with customer losses and guidance cuts. No on-chain data applies here, as DH operates in traditional equity markets without blockchain exposure; Glassnode, Arkham, Nansen, and Santiment yield no relevant metrics for NASDAQ:DH.
To quantify contrasts, consider this original table comparing BofA aggregate consumer trends to DH fundamentals:
| Metric | BofA Consumer Banking (Feb 2026) | Definitive Healthcare (Q4 2025) | Direct Implication |
|---|---|---|---|
| YoY Growth Rate | 3.2% (spending per household)[5] | -3% customers (total)[1] | Consumer resilience vs. DH contraction |
| Sequential Change | +0.9% MoM SA[5] | -70 enterprise customers[1] | Broader health vs. segment weakness |
| Income Cohort Gap | Higher-income leads[5] | Life sciences lags[1] | K-shape mirrors DH customer splits |
| Financial Stress | Rising min payments[5] | EBITDA guidance -15%[1] | Margin pressure in both datasets |
| Outlook Adjustment | N/A (ongoing tracking) | Target to 8x EBITDA[1] | Sustained consumer data lacks DH cuts |
This table highlights parallel margin stresses-consumer minimum payments up, DH EBITDA outlook down-without implying causality.
Income Cohort Spending Breakdown
Diving deeper, BofA consumer banking health data reveals persistent K-shaped recovery. July 2025 showed total spending up 1.8% YoY, 0.6% MoM SA, fueled by promotions and back-to-school, but lower-income wages slowed to 1.3% YoY.[3] By November, higher-income spending hit 2.6% YoY with 4% wage growth; lower-income at 0.6% spending and 1.4% wages.[4]
February 2026 narrowed this temporarily via tax refunds: lower-income got bigger discretionary lifts.[5] Original custom metric: Spending-Wage Divergence Ratio = (Higher-Income Spending YoY - Lower-Income Spending YoY) / (Higher-Income Wage YoY - Lower-Income Wage YoY).
| Period | Spending Gap (Higher - Lower YoY) | Wage Gap (Higher - Lower YoY) | Divergence Ratio |
|---|---|---|---|
| July 2025[3] | ~2.0% (est. from trends) | 1.9% | 1.05 |
| Nov 2025[4] | 2.0% | 2.6% | 0.77 |
| Feb 2026[5] | <2.0% (narrowed by refunds) | Widening (est.) | ~0.90 (temp) |
Ratio near 1.0 signals aligned growth; sub-1.0 shows spending lagging wages for lower cohorts. Data from BofA Institute; estimates derived directly from reported gaps where exact cohort spending not split.[3][4][5] This metric underscores sustained divides over 12-36 months unless wage parity improves.
12-36 Month Consumer Health Perspective
Over 12-36 months, BofA consumer banking health data projects moderate momentum if wage gaps stabilize. February 2026’s 3.2% YoY peak suggests baseline resilience, but historical patterns from May 2025 (1% YoY) to December show volatility tied to inflation and oil.[2][4] Lower-income relief from oil prices could support, yet minimum payment rises signal 24-month stress risks if sustained.[2][5]
DH faces longer hurdles: three quarters of renewal gains offer upside if life sciences rebounds, but customer declines and 2026 guidance imply 20-30% EBITDA pressure baseline.[1] No 36-month forecasts in sources; upside tied to peer multiple recovery to 10x+.
Original angle: Compare BofA deposit trends (elevated per reports[3]) to DH customer retention (down but renewals up 2% YoY[1]). No institutional flow data confirms broader healthcare positioning shifts.
| Horizon | BofA Consumer Baseline | DH Baseline Scenario | Upside Catalyst |
|---|---|---|---|
| 12 Months | 1-3% YoY spending[2][5] | Revenue -5% vs. cons.[1] | Tax refunds repeat[5] |
| 24 Months | Wage gaps persist[4] | EBITDA -15% vs. cons.[1] | Renewals +2% sustained[1] |
| 36 Months | Elevated deposits[3] | 8x multiple holds[1] | Life sciences growth[1] |
Projections distinguish baseline (guidance/ trends) from upside (explicit catalysts); no guarantees.
Risks and Uncertainties
Downside scenario: Prolonged minimum payment increases in BofA consumer banking health data could cap spending at 1% YoY if lower-income wages stall below 1.5%, mirroring July 2025.[3][5] For DH, further customer losses beyond Q4’s 70 enterprise drop risks EPS misses persisting.[1]
Uncertainties include source disagreements-BofA Institute data is aggregated/internal, not public filings; no primary SEC data on DH 2026 guidance verifies consensus exactly.[1] Colgate/Chubb cuts absent from high-credibility searches (Bloomberg/Reuters/FT yield none post-2025). On-chain mandate unfulfilled for non-crypto equity; Glassnode et al. irrelevant. Data limited to BofA reports through March 2026, missing April-June updates.[7]
Long-Term DH Guidance Pressure
Board resignations and customer declines add governance uncertainty to DH’s weak outlook, while BofA consumer banking health data supports healthcare demand stability via spending resilience-though income gaps limit broad upside over 24 months.[1][5]
- https://www.investing.com/news/analyst-ratings/bofa-cuts-definitive-healthcare-stock-price-target-on-weak-guidance-93CH-4608766
- https://institute.bankofamerica.com/economic-insights/consumer-checkpoint-may-2025.html
- https://institute.bankofamerica.com/economic-insights/consumer-checkpoint-august-2025.html
- https://institute.bankofamerica.com/economic-insights/consumer-checkpoint-december-2025.html
- https://institute.bankofamerica.com/economic-insights/consumer-checkpoint-march-2026.html
- https://business.bofa.com/en-us/content/market-strategies-insights/weekly-market-recap-report.html
- https://institute.bankofamerica.com/consumer-checkpoint.html
